Drugs / KRN5500
KRN5500
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00017238 | Feb 2002 → Nov 2008 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002923 | May 1997 → Jan 2000 | cancer of unknown primary site | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00474916 | Jun 2006 → Mar 2009 | neuropathy, painful | DARA Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRN5500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017238 ↗ |
| Known as | NSC 650426 | “A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors” NCT00017238 ↗ |
| Known as | SPK-241 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2074765 ↗ |
| Modality | Small molecule | — CHEMBL2074765 ↗ |
| Route | Intravenous | “KRN5500 IV” NCT00002923 ↗ |